Join Transform 2021 this July 12-16. Register for the AI event of the year.



Aerovance
, a Berkeley, Calif biopharmaceutical company looking to find a partner for its asthma treatement, Aerovant, reached back to year-old news and announced it has finished raising $60 million in a third round of financing.

There is “substantial very, very strong interest” by pharmaceutical and biotech companies in the asthma treatment, the company told VentureWire (sub required), though no specifics were given.

Here is the company’s announcement of the funding last year.

The company’s drugs target severe respiratory and inflammatory diseases. The financing was led by Clarus Ventures, and included Alta Partners and existing investors Apax Partners, Lehman Brothers, NGN Capital and Burrill & Co.

Aerovance received $28 million of the funding last year, and has since received an additional $32 million.

VentureBeat

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
  • up-to-date information on the subjects of interest to you
  • our newsletters
  • gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
  • networking features, and more
Become a member